Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Frequency Therapeutics Inc is a biotechnology business based in the US. Frequency Therapeutics shares (FREQ) are listed on the NASDAQ and all prices are listed in US Dollars. Frequency Therapeutics employs 83 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.75|
|52-week range||$6.60 - $58.37|
|50-day moving average||$7.23|
|200-day moving average||$8.66|
|Wall St. target price||$12.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.58|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-0.88%|
|1 month (2021-09-22)||-7.28%|
|3 months (2021-07-22)||-14.34%|
|6 months (2021-04-22)||-33.30%|
|1 year (2020-10-22)||-69.18%|
|2 years (2019-10-22)||-50.84%|
|3 years (2018-10-18)||N/A|
|5 years (2016-10-18)||N/A|
|Revenue TTM||$35.3 million|
|Gross profit TTM||$5 million|
|Return on assets TTM||-15.7%|
|Return on equity TTM||-32.71%|
|Market capitalisation||$244.7 million|
TTM: trailing 12 months
There are currently 4.6 million Frequency Therapeutics shares held short by investors – that's known as Frequency Therapeutics's "short interest". This figure is 9.2% down from 5.1 million last month.
There are a few different ways that this level of interest in shorting Frequency Therapeutics shares can be evaluated.
Frequency Therapeutics's "short interest ratio" (SIR) is the quantity of Frequency Therapeutics shares currently shorted divided by the average quantity of Frequency Therapeutics shares traded daily (recently around 199037.38197425). Frequency Therapeutics's SIR currently stands at 23.3. In other words for every 100,000 Frequency Therapeutics shares traded daily on the market, roughly 23300 shares are currently held short.
However Frequency Therapeutics's short interest can also be evaluated against the total number of Frequency Therapeutics shares, or, against the total number of tradable Frequency Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Frequency Therapeutics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Frequency Therapeutics shares in existence, roughly 130 shares are currently held short) or 0.142% of the tradable shares (for every 100,000 tradable Frequency Therapeutics shares, roughly 142 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Frequency Therapeutics.
Find out more about how you can short Frequency Therapeutics stock.
We're not expecting Frequency Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Frequency Therapeutics's shares have ranged in value from as little as $6.6 up to $58.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Frequency Therapeutics's is 0.5414. This would suggest that Frequency Therapeutics's shares are less volatile than average (for this exchange).
Frequency Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.